How I treat plasma cell leukemia

Blood

Volumn 120, Issue 12, 2012, Pages 2376-2389

  Van De Donk, Niels W C J ^a,b   Lokhorst, Henk M ^b   Anderson, Kenneth C ^a   Richardson, Paul G ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALLOPURINOL; ANTIINFECTIVE AGENT; BETA 2 MICROGLOBULIN; BORTEZOMIB; CALCIUM; CD19 ANTIGEN; CD20 ANTIGEN; CD23 ANTIGEN; CD27 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CD71 ANTIGEN; CD9 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; HEMOGLOBIN; HLA DR ANTIGEN; LACTATE DEHYDROGENASE; LENALIDOMIDE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; PAMIDRONIC ACID; STEM CELL FACTOR RECEPTOR; THALIDOMIDE; UNINDEXED DRUG; VINCRISTINE;

ADULT; ALBUMIN BLOOD LEVEL; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CALCIUM BLOOD LEVEL; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CASE REPORT; CHROMOSOME ANALYSIS; CIRCULATING TUMOR CELL; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DONOR LYMPHOCYTE INFUSION; EPIGENETICS; FATIGUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HEMOGLOBIN BLOOD LEVEL; HORMONAL THERAPY; HUMAN; HYPERCALCEMIA; IMMUNOPHENOTYPING; KIDNEY FAILURE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MENORRHAGIA; MENSTRUATION; METASTASIS; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROLOGIC DISEASE; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OPHTHALMOPLEGIA; PALLOR; PHYSICAL EXAMINATION; PLASMA CELL LEUKEMIA; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; REHYDRATION; REVIEW; SALVAGE THERAPY; SKIN BRUISING; SPLENOMEGALY; SYSTEMIC DISEASE; THROMBOCYTE COUNT; TUMOR ESCAPE; TUMOR LYSIS SYNDROME; WEIGHT REDUCTION;

EID: 84866605778     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-05-408682     Document Type: Review

References (100)

1. Kyle RA, Maldonado JE, Bayrd ED. Plasma cell leukemia: report on 17 cases. Arch Intern Med. 1974;133(5):813-818.
2. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749-757.
3. Gluzinski A, Reichenstein M. Myeloma und leucaemia lymphatica plasmocellularis Wien Klin Wochenschr. 1906;12:336-339.
4. Avet-Loiseau H, Roussel M, Campion L, et al. Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience. Leukemia. 2012;26(1):158-159.
5. Tiedemann RE, Gonzalez-Paz N, Kyle RA, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia. 2008;22(5):1044-1052.
6. Garcia-Sanz R, Orfao A, Gonzalez M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999;93(3):1032-1037.
7. Noel P, Kyle RA. Plasma cell leukemia: an evaluation of response to therapy. Am J Med. 1987;83(6):1062-1068.
8. Dimopoulos MA, Palumbo A, Delasalle KB, Alexanian R. Primary plasma cell leukaemia. Br J Haematol. 1994;88(4):754-759.
9. Vela-Ojeda J, Garcia-Ruiz Esparza MA, Rosas-Cabral A, et al. Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia. Ann Hematol. 2002;81(7):362-367.
10. Usmani SZ, Nair B, Qu P, et al. Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling, and clinical outcome with Total Therapy protocols [published online ahead of print April 17, 2012]. Leukemia. doi: 10.1038/leu.2012.107.
11. Hugo ZP, Perry MC, Steensma DP. Extreme leukocytosis in the 21st Century is often iatrogenic [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112(11):5401.
12. Pasqualetti P, Festuccia V, Collacciani A, Acitelli P, Casale R. Plasma cell leukemia: a report on 11 patients and review of the literature. Panminerva Med. 1996;38(3):179-184.
13. Avet-Loiseau H, Daviet A, Brigaudeau C, et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Blood. 2001;97(3):822-825.
14. Avet-Loiseau H, Li C, Magrangeas F, et al. Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol. 2009;27(27):4585- 4590.
15. Jimenez-Zepeda VH, Neme-Yunes Y, Braggio E. Chromosome abnormalities defined by conventional cytogenetics in plasma cell leukemia: what have we learned about its biology? Eur J Haematol. 2011;87(1):20-27.
16. Chang H, Qi X, Yeung J, Reece D, Xu W, Patterson B. Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia. Leuk Res. 2009;33(2):259-262.
17. Chiecchio L, Dagrada GP, White HE, et al. Frequent upregulation of MYC in plasma cell leukemia. Genes Chromosomes Cancer. 2009;48(7):624-636.
18. Fonseca R, Debes-Marun CS, Picken EB, et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood. 2003;102(7):2562-2567.
19. Johnson MR, Del Carpio-Jayo D, Lin P, et al. Primary plasma cell leukemia: morphologic, immunophenotypic, and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantation. Ann Diagn Pathol. 2006;10(5):263-268.
20. Walters M, Olteanu H, Van Tuinen P, Kroft SH. CD23 expression in plasma cell myeloma is specific for abnormalities of chromosome 11, and is associated with primary plasma cell leukaemia in this cytogenetic sub-group. Br J Haematol. 2010;149(2):292-293.
21. Mosca L, Musto P, Fabris S, et al. Integrative genomic analysis of primary plasma cell leukemia revealed strong gene and microRNA dosage effect [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):4040.
22. Musto P, D'Auria F, Petrucci MT, et al. Final results of a phase II study evaluating lenalidomide in combination with low dose dexamethasone as first line therapy for primary plasma cell leukemia [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):2925.
23. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007;109(8):3489-3495.
24. Fonseca R, Blood EA, Oken MM, et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood. 2002;99(10):3735-3741.
25. Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101(11):4569-4575.
26. Lloveras E, Granada I, Zamora L, et al. Cytogenetic and fluorescence in situ hybridization studies in 60 patients with multiple myeloma and plasma cell leukemia. Cancer Genet Cytogenet. 2004;148(1):71-76.
27. Gutierrez NC, Hernandez JM, Garcia JL, et al. Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization. Leukemia. 2001;15(5):840-845.
28. Chang H, Qi X, Jiang A, Xu W, Young T, Reece D. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Bone Marrow Transplant. 2010;45(1):117-121.
29. Sumegi J, Hedberg T, Bjorkholm M, et al. Amplification of the c-myc oncogene in human plasmacell leukemia. Int J Cancer. 1985;36(3):367-371.
30. Fabris S, Storlazzi CT, Baldini L, et al. Heterogeneous pattern of chromosomal breakpoints involving the MYC locus in multiple myeloma. Genes Chromosomes Cancer. 2003;37(3):261-269.
31. Neri A, Baldini L, Trecca D, Cro L, Polli E, MaioloAT. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood. 1993;81(1):128-135.
32. Bezieau S, Devilder MC, Avet-Loiseau H, et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat. 2001;18(3):212-224.
33. Corradini P, Ladetto M, Voena C, et al. Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. Blood. 1993;81(10):2708-2713.
34. Ortega MM, Faria RM, Shitara ES, et al. N-RAS and K-RAS gene mutations in Brazilian patients with multiple myeloma. Leuk Lymphoma. 2006;47(2):285-289.
35. Walker BA, Wardell CP, Boyd KD, et al. Hypermethylation is a key feature of the transition of multiple myeloma to plasma cell leukemia [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):535.
36. Walker BA, Wardell CP, Chiecchio L, et al. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood. 2011;117(2):553-562.
37. Kraj M, Kopec-Szlezak J, Poglod R, Kruk B. Flow cytometric immunophenotypic characteristics of 36 cases of plasma cell leukemia. Leuk Res. 2011;35(2):169-176.
38. Pellat-Deceunynck C, Barille S, Jego G, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia. 1998;12(12):1977-1982.
39. Pellat-Deceunynck C, Barille S, Puthier D, et al. Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization. Cancer Res. 1995;55(16):3647-3653.
40. Barille S, Collette M, Bataille R, Amiot M. Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Blood. 1995;86(8):3151-3159.
41. Schmidmaier R, Mandl-Weber S, Gaul L, et al. Inhibition of lymphocyte function associated antigen 1 by LFA878 induces apoptosis in multiple myeloma cells and is associated with downregulation of the focal adhesion kinase/phosphatidylinositol 3 kinase/Akt pathway. Int J Oncol. 2007;31(4):969-976.
42. Edvardsen K, Chen W, Rucklidge G, Walsh FS, Obrink B, Bock E. Transmembrane neural cell-adhesion molecule (NCAM), but not glycosylphosphatidylinositol-anchored NCAM, downregulates secretion of matrix metalloproteinases. Proc Natl Acad Sci U S A. 1993;90(24):11463-11467.
43. Ohtake K, Takeuchi T, Saito K, et al. Integrin VLA-5 negative primary plasma cell leukemia. Intern Med. 1993;32(7):565-568.
44. Barker HF, Hamilton MS, Ball J, Drew M, Franklin IM. Expression of adhesion molecules LFA-3 and N-CAM on normal and malignant human plasma cells. Br J Haematol. 1992;81(3):331-335.
45. Singh ZN, Owens RB, Nair B, Shaughnessy J Jr., Barlogie B. Loss of chemokine receptor expression and tetraspanins is correlated with extramedullary disease in multiple myeloma [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):2983.
46. Perez-Andres M, Almeida J, Martin-Ayuso M, et al. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia. 2005;19(3):449-455.
47. Clayberger C, Wright A, Medeiros LJ, et al. Absence of cell surface LFA-1 as a mechanism of escape from immunosurveillance. Lancet. 1987;2(8558):533-536.
48. RamsinghG,Mehan P, Luo J, Vij R, Morgensztern D. Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004. Cancer. 2009;115(24):5734-5739.
49. Costello R, Sainty D, Bouabdallah R, et al. Primary plasma cell leukaemia: a report of 18 cases. Leuk Res. 2001;25(2):103-107.
50. Drake MB, Iacobelli S, van Biezen A, et al. Primary plasma cell leukemia and autologous stem cell transplantation. Haematologica. 2010;95(5):804-809.
51. Pagano L, Valentini CG, De Stefano V, et al. Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. Ann Oncol. 2011; 22(7):1628-1635.
52. Kraj M, Kopec-Szlezak J, Poglod R, Kruk B. Flow cytometric immunophenotypic characteristics of plasma cell leukemia. Folia Histochem Cytobiol. 2011;49(1):168-182.
53. Woodruff RK, Malpas JS, Paxton AM, Lister TA. Plasma cell leukemia (PCL): a report on 15 patients. Blood. 1978;52(4):839-845.
54. Colovic M, Jankovic G, Suvajdzic N, Milic N, Dordevic V, Jankovic S. Thirty patients with primary plasma cell leukemia: a single center experience. Med Oncol. 2008;25(2):154-160.
55. Jimenez-Zepeda VH, Dominguez VJ. Plasma cell leukemia: a rare condition. Ann Hematol. 2006;85(4):263-267.
56. Saccaro S, Fonseca R, Veillon DM, et al. Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am J Hematol. 2005;78(4):288-294.
57. Bernasconi C, Castelli G, Pagnucco G, Brusamolino E. Plasma cell leukemia: a report on 15 patients. Eur J Haematol Suppl. 1989;51:76-83.
58. Buda G, Carulli G, Orciuolo E, et al. CD23 expression in plasma cell leukaemia. Br J Haematol. 2010;150(6):724-725.
59. Guikema JE, Hovenga S, Vellenga E, et al. CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease. Br J Haematol. 2003;121(1):36-43.
60. Hundemer M, Klein U, Hose D, et al. Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14). Bone Marrow Transplant. 2007;40(11):1033-1037.
61. Musto P, Rossini F, Gay F, et al. Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer. 2007;109(11):2285-2290.
62. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516- 2520.
63. Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K. New drugs for myeloma. Oncologist. 2007;12(6):664-689.
64. Chaoui D, Leleu X, Roussel M, et al. Has the prognostic of primary plasma cell leukemia improved with new drugs? [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114(22):3869.
65. Neben K, Lokhorst HM, Jauch A, et al. Administration of bortezomib before and after autologous stem-cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2012;119(4):940-948.
66. Shaughnessy JD, Zhou Y, Haessler J, et al. TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3. Br J Haematol. 2009;147(3):347-351.
67. Avet-Loiseau H, Leleu X, Roussel M, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol. 2010;28(30):4630-4634.
68. Esparis-Ogando A, Alegre A, Aguado B, et al. Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer. 2005;114(4):665-667.
69. Katodritou E, Verrou E, Gastari V, Hadjiaggelidou C, Terpos E, Zervas K. Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome? Leuk Res. 2008;32(7):1153-1156.
70. Grassinger J, Sudhoff T, Andreesen R, Hennemann B. Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib. Ann Hematol. 2006;85(2):132-133.
71. D'Arena G, Valentini CG, Pietrantuono G, et al. Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party. Ann Oncol. 2012;23(6):1499-1502.
72. Libby E, Candelaria-Quintana D, Moualla H, Abdul-Jaleel M, Rabinowitz I. Durable complete remission of primary plasma cell leukemia with the bortezomib plus melphalan and prednisone (VMP) regimen. Am J Hematol. 2010;85(9):733-734.
73. Al-Nawakil C, Tamburini J, Bardet V, et al. Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy. Leuk Lymphoma. 2008;49(10):2012-2014.
74. Lebon D, Gruson B, Garidi R, et al. Bortezomib, doxorubicin and dexamethasone (PAD) prior to high-dose melphalan/autologous stem cell transplantation for newly diagnosed plasma cell dycrasias [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114(22):4960.
75. Lebovic D, Zhang L, Alsina M, et al. Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience. Clin Lymphoma Myeloma Leuk. 2011;11(6):507-511.
76. Petrucci MT, Martini V, Levi A, et al. Thalidomide does not modify the prognosis of plasma cell leukemia patients: experience of a single center. Leuk Lymphoma. 2007;48(1):180-182.
77. Gemmel C, Cremer FW, Weis M, et al. Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantation. Ann Hematol. 2002;81(2):119-123.
78. Johnston RE, Abdalla SH. Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia. Leuk Lymphoma. 2002;43(2):351-354.
79. Bauduer F. Efficacy of thalidomide in the treatment of VAD-refractory plasma cell leukaemia appearing after autologous stem cell transplantation for multiple myeloma. Br J Haematol. 2002;117(4):996-997.
80. Wohrer S, Ackermann J, Baldia C, et al. Effective treatment of primary plasma cell leukemia with thalidomide and dexamethasone: a case report. Hematol J. 2004;5(4):361-363.
81. Murthy V, Mwirigi A, Ward S, Rassam SMB. Rapid and excellent response to hyper CVAD, particularly with thalidomide, in plasma cell leukaemia and long term remissions following allogeneic stem cell transplantation [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114(22):4963.
82. Musto P, Pietrantuono G, Guariglia R, et al. Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia. Leuk Res. 2008;32(10):1637-1638.
83. Guglielmelli T, Merlini R, Giugliano E, Saglio G. Lenalidomide, melphalan, and prednisone association is an effective salvage therapy in relapsed plasma cell leukaemia. J Oncol. 2009;2009:867380.
84. Goyal M, Mohammad N, Palanki SD, Vaniawala SN. Primary plasma cell leukemia with light chain secretion and multiple chromosomal abnormalities: how successfully treated?Acase report with review of literature. Indian J Med Paediatr Oncol. 2010;31(3):96-100.
85. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983;2(8354):822-824.
86. Mahindra A, Kalaycio ME, Vela-Ojeda J, et al. Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. Leukemia. 2012;26(5):1091-1097.
87. Lebovic DJ, Baz R, Alsina M, et al. Cytogenetics and clinical outcomes of plasma cell leukemia patients: a single institution experience [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114(22):4932.
88. Ladetto M, Pagliano G, Ferrero S, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol. 2010;28(12):2077-2084.
89. Cavo M, Pantani L, Patriarca F, et al. Superior complete response rate (CR) and progressionfree survival (PFS) with bortezomib-thalidomide- dexamethasone (VTD) versus thalidomide-dexamethasone (TD) as consolidation therapy after autologous stem-cell transplantation (ASCT) in multiple myeloma (MM) [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):1871.
90. Attal M, Lauwers Vc Marit G, et al. Maintenance treatment with lenalidomide after transplantation for MYELOMA: final analysis of the IFM 2005-02 [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):310.
91. Paiva B, Gutierrez NC, Rosinol L, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood. 2012;119(3):687-691.
92. Avet-Loiseau H, Caillot D, Marit G, et al. Longterm maintenance with lenalidomide improves progression free survival in myeloma patients with high-risk cytogenetics: an IFM study [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):1944.
93. Morgan GJ, Gregory WM, Davies FE, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood. 2012;119(1):7-15.
94. Ludwig H, Durie BG, McCarthy P, et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood. 2012;119(3):3003-3015.
95. van de Donk NW, Lokhorst HM, Dimopoulos M, et al. Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev. 2011;37(4):266-283.
96. Jaskiewicz AD, Herrington JD, Wong L. Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia. Pharmacotherapy. 2005;25(12):1820-1825.
97. Benson DM Jr, Smith MK. Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia. Leuk Lymphoma. 2007;48(7):1423-1425.
98. Oka S, Yokote T, Akioka T, et al. Successful treatment of multi-agent chemotherapy with rituximab for IgM plasma cell leukemia. Leuk Res. 2006;30(12):1581-1583.
99. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21-33.
100. Kucharz EJ. [Wladyslaw Antoni Gluzinski: an eminent Polish internist, founder of the Polish Society of Internal Medicine]. Pol Arch Med Wewn. 2007;117(5):270-273.